{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=29", "query": { "intervention": "A PROTEIN level", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 1383, "total_pages": 139, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T06:49:46.374Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00837616", "title": "Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Turner Syndrome", "Hypogonadism", "Premature Ovarian Failure" ], "interventions": [ { "name": "17 B estradiol orally", "type": "DRUG" }, { "name": "17 B estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nemours Children's Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": "20 Years", "sex": "FEMALE", "summary": "13 Years to 20 Years · Female only" }, "enrollment_count": 41, "start_date": "2009-01", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2023-05-16", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00837616" }, { "nct_id": "NCT05986240", "title": "Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Danvatirsen + Venetoclax", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2024-05-08", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 2, "location_summary": "The Bronx, New York • Houston, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05986240" }, { "nct_id": "NCT04421560", "title": "Pembrolizumab, Ibrutinib and Rituximab in PCNSL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Central Nervous System Lymphoma", "Recurrent Cancer", "Refractory Cancer", "Relapsed Cancer" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-08-01", "completion_date": "2027-01-05", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421560" }, { "nct_id": "NCT00151320", "title": "Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bortezomib, CHOP, Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2004-01", "completion_date": "2013-04-24", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Omaha, Nebraska • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151320" }, { "nct_id": "NCT01765790", "title": "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Adenocarcinoma of the Colon or Rectum", "Malignant Solid Tumors" ], "interventions": [ { "name": "Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2012-06-14", "completion_date": "2016-07-28", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Houston, Texas + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01765790" }, { "nct_id": "NCT00100906", "title": "Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2004-08", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-08-16", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100906" }, { "nct_id": "NCT00068250", "title": "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "temozolomide 100 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 150 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 200 mg/m^2", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "post-radiation therapy temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2003-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 26, "location_summary": "Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville Beach", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068250" }, { "nct_id": "NCT07079631", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "BNT314", "type": "BIOLOGICAL" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 1", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 2", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2025-07-18", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07079631" }, { "nct_id": "NCT06614192", "title": "A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2024-11-08", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 24, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06614192" }, { "nct_id": "NCT01951729", "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pre-diabetes" ], "interventions": [ { "name": "Control", "type": "DRUG" }, { "name": "Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP without atropine", "type": "DRUG" }, { "name": "Placebo with atropine", "type": "DRUG" }, { "name": "Xenin-25 with atropine", "type": "DRUG" }, { "name": "GIP with atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 with atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2013-03-13", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-16T06:49:46.374Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951729" } ] }